During the last session, Revance Therapeutics Inc (NASDAQ:RVNC)’s traded shares were 2.64 million, with the beta value of the company hitting 1.15. At the end of the trading day, the stock’s price was $3.29, reflecting an intraday loss of -7.84% or -$0.28. The 52-week high for the RVNC share is $37.98, that puts it down -1054.41 from that peak though still a striking -7.6% loss since the share price plummeted to a 52-week low of $3.54. The company’s market capitalization is $342.88M, and the average trade volume was 1.79 million shares over the past three months.
Revance Therapeutics Inc (NASDAQ:RVNC) trade information
Revance Therapeutics Inc (RVNC) registered a -7.84% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -7.84% in intraday trading to $3.29, hitting a weekly high. The stock’s 5-day price performance is -13.19%, and it has moved by -30.00% in 30 days. Based on these gigs, the overall price performance for the year is -89.60%.
Revance Therapeutics Inc (RVNC) estimates and forecasts
Statistics show that Revance Therapeutics Inc has outperformed its competitors in share price, compared to the industry in which it operates. Revance Therapeutics Inc (RVNC) shares have gone down -61.97% during the last six months, with a year-to-date growth rate more than the industry average at 43.34% against 12.90. In the rating firms’ projections, revenue will increase 20.40% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 56.63M as predicted by 7 analyst(s). Meanwhile, a consensus of 7 analyst(s) estimates revenue growth to 68.21M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 49.33M and 58.13M respectively. In this case, analysts expect current quarter sales to grow by 14.80% and then jump by 17.30% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 0.57%. While earnings are projected to return 20.20% in 2024, the next five years will return 11.60% per annum.
RVNC Dividends
Revance Therapeutics Inc is due to release its next quarterly earnings in May. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
